Optimer to Market Dificid Drug With Cubist Pharmaceuticals
This article is for subscribers only.
Optimer Pharmaceuticals Inc. said it will co-market its fidaxomicin drug with Cubist Pharmaceuticals Inc. after winning U.S. panel backing for the antibiotic that fights a deadly bacterium often caught in hospitals.
Fidaxomicin, to be sold as Dificid, may be approved May 30 by the U.S. Food and Drug Administration and become San Diego-based Optimer’s first product.